FeesSafety
Pluang+

Bitget Wallet adds 1,700 tokenized US stocks from its own issuer Reality for direct self-custody trading.

Market News
15 Sep 2026
Unchained
View Source
Bullish
Bitget Wallet adds 1,700 tokenized US stocks from its own issuer Reality for direct self-custody trading.

Bitget Wallet has integrated Reality, its own regulated tokenized-asset issuer, allowing users to trade over 1,700 tokenized US stocks and ETFs with full self-custody. These tokens, called rTokens, are backed 1:1 by actual shares held at a registered broker-dealer, with dividends paid in stablecoins and stock splits reflected automatically. This addition makes Reality the third tokenized-equity provider on Bitget Wallet, offering global users easier access to US equities without needing foreign brokerage accounts. The move comes amid ongoing debates about tokenized stocks' regulatory status and market acceptance.

The Bitget Wallet's addition of 1,700 tokenized US stocks and ETFs from its issuer Reality provides context for digital asset markets. For readers following major cryptocurrencies on Pluang as of Sep 16, 2026 03:28 WIB: only 4 of 50 major cryptocurrencies rose, while 45 fell. Among them, BAL gained 11.14% to Rp16.297 with a typical hold time of 85 days, contrasting with XTZ and XLM which dropped by 10.03% and 9.62% to Rp4.384 and Rp3.109 respectively, with XTZ showing a strong buy order activity of 97%.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
46 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
46 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
46 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App